Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro

NeuroToxicology

Volumn 33, Issue 1, 2012, Pages 138-146

  Harvey, Benjamin S ^a   Ohlsson, Katharina S ^b   Mååg, Jesper L V ^c   Musgrave, Ian F ^a   Smid, Scott D ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Amyloid; Cannabinoid; Neuroprotection; Oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN; ANANDAMIDE; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; HYDROGEN PEROXIDE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; ELECTRON MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; MOUSE; MUSCLE FIBRIL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANIMALS; ANTIOXIDANTS; ARACHIDONIC ACIDS; CANNABINOIDS; CELL LINE, TUMOR; CELL SURVIVAL; CHROMANS; DRUG INTERACTIONS; GENE EXPRESSION REGULATION; HUMANS; HYDROGEN PEROXIDE; INDOLES; LIPID PEROXIDATION; MICROSCOPY, ELECTRON, TRANSMISSION; NEUROBLASTOMA; OXIDATIVE STRESS; PC12 CELLS; PEPTIDE FRAGMENTS; RATS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; THIAZOLES;

EID: 84855998880     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2011.12.015     Document Type: Article

References (56)

1. Behl C., Davis J.B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid β protein toxicity. Cell 1994, 77:817-827.
2. Benito C., Nunez E., Tolon R.M., Carrier E.J., Rabano A., Hillard C.J., et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 2003, 23:11136-11141.
3. Bernstein S.L., Dupuis N.F., Lazo N.D., Wyttenbach T., Condron M.M., Bitan G., et al. Amyloid-beta protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. Nat Chem 2009, 1:326-331.
4. Bieschke J., Russ J., Friedrich R.P., Ehrnhoefer D.E., Wobst H., Neugebauer K., et al. EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci USA 2010, 107:7710-7715.
5. Bisogno T., Di Marzo V. The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses. Curr Pharm Des 2008, 14:2299-3305.
6. Carrano A., Hoozemans J.J., van der Vies S.M., Rozemuller A.J., van Horssen J., de Vries H.E. Amyloid beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal 2011, 10.1089/ars.2011.3895.
7. Casetta I., Govoni V., Granieri E. Oxidative stress, antioxidants and neurodegenerative diseases. Curr Pharm Des 2005, 11:2033-2052.
8. Castillo A., Tolon M.R., Fernandez-Ruiz J., Romero J., Martinez-Orgado J. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiol Dis 2010, 37:434-440.
9. Craggs L., Kalaria R.N. Revisiting dietary antioxidants, neurodegeneration and dementia. Neuroreport 2011, 22:1-3.
10. De Petrocellis L., Di Marzo V. Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J Neuroimmun Pharmacol 2010, 5:103-121.
11. Demerle-Pallardy C., Gillard-Roubert V., Marin J.G., Auguet M., Chabrier P.E. In vitro antioxidant neuroprotective activity of BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation. J Neurochem 2000, 74:2079-2086.
12. Eljaschewitsch E., Witting A., Mawrin C., Lee T., Schmidt P.M., Wolf S., et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006, 49:67-79.
13. Esposito G., De Filippis D., Carnuccio R., Izzo A.A., Iuvone T. The marijuana component cannabidiol inhibits β-amyloid-induced tau protein hyperphosphorylation through Wnt/β-catenin pathway rescue in PC12 cells. J Mol Med 2006, 84:253-258.
14. Esposito G., De Filippis D., Maiuri M.C., De Stefano D., Carnuccio R., Iuvone T. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in b-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kB involvement. Neurosci Lett 2006, 399:91-95.
15. Esposito G., Scuderi C., Savani C., Steardo L., De Filippis D., Cottone P., et al. Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression. Br J Pharmacol 2007, 151:1272-1279.
16. Eubanks L.M., Rogers C.J., Beuscher Koob G.F., Olson A.J., Dickerson T.J., et al. A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol Pharm 2006, 3:773-777.
17. Fernández-Ruiz J., Romero J., Velasco G., Tolón R.M., Ramos J.A., Guzmán M. Cannabinoid CB2 receptor: a new target for controlling neural cell survival. Trends Pharmacol Sci 2007, 28:39-45.
18. Fowler C.J. The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action. Br J Pharmacol 2007, 152:594-601.
19. Fowler C.J., Rojo M.L., Rodriguez-Gaztelumendi A. Modulation of the endocannabinoid system: neuroprotection or neurotoxicity. Exp Neurol 2010, 224:37-47.
20. Halliwell B. Oxidative stress and neurodegeneration: where are we now. J Neurochem 2006, 97:1634-1658.
21. 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998, 95:8268-8273.
22. Hix S., Kadiiska M.B., Mason R.P., Augusto O. In vivo metabolism of tert-butyl hydroperoxide to methyl radicals, EPR spin-trapping and DNA methylation studies. Chem Res Toxicol 2000, 13:1056-1064.
23. Hu X., Crick S.L., Bu G., Frieden C., Pappu R.V., Lee J-M. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc Natl Acad Sci USA 2009, 106:20324-20329.
24. Hudson S.A., Ecroyd H., Kee T.W., Carver J.A. The thioflavin T fluorescence assay for amyloid fibril detection can be biased by the presence of exogenous compounds. FEBS J 2009, 276:5960-5972.
25. Hudson S.A., Ecroyd H., Musgrave I.F., Dehle F.C., Carver J.A. (-)-Epigallocatechin-3-Gallate (EGCG) maintains κ-casein in Its pre-fibrillar state without redirecting Its aggregation pathway. J Mol Biol 2009, 392:689-700.
26. Iuvone T., Esposito G., De Filippis D., Bisogno T., Petrosino S., Scuderi C., et al. Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro. J Mol Med 2007, 85:1379-1392.
27. Iuvone T., Esposito G., De Filippis D., Scuderi C., Steardo L. Cannabidiol: a promising drug for neurodegenerative disorders. CNS Neurosci Ther 2009, 15:65-75.
28. Iuvone T., Esposito G., Esposito R., Santamaria R., Di Rosa M., Izzo A.A. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem 2004, 89:134-141.
29. Kim S.H., Won S.J., Mao X.O., Jin K., Greenberg D.A. Involvement of protein kinase A in cannabinoid receptor-mediated protection from oxidative neuronal injury. J Pharmacol Exp Ther 2005, 313:88-94.
30. Klegeris A., Bissonnette C.J., McGeer P.L. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol 2003, 139:775-786.
31. Liu Z., Tao X., Zhang C., Lu Y., Wei D. Protective effects of hyperoside (quercetin-3-o-galactoside) to PC12 cells against cytotoxicity induced by hydrogen peroxide and tert-butyl hydroperoxide. Biomed Pharmacother 2005, 59:481-490.
32. Maccarrone M., Lorenzon T., Bari M., Melino G., Finazzi-Agro A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem 2000, 275:31938-31945.
33. Marini P., Moriello A.S., Cristino L., Palmery M., De Petrocellis L., Di Marzo V. Cannabinoid CB1 receptor elevation of intracellular calcium in neuroblastoma SH-SY5Y cells: interactions with muscarinic and delta-opioid receptors. Biochim Biophys Acta 2009, 1793:1289-1303.
34. Milton N.G.N. Anandamide and noladin ether prevent neurotoxicity of the human amyloid-β peptide. Neurosci Lett 2002, 332:127-130.
35. Mnich K., Finn D.P., Dowd E., Gorman A.M. Inhibition by anandamide of 6-hydroxydopamine-induced cell death in PC12 cells. Int J Cell Biol 2010, 2010:818497.
36. Noonan J., Tanveer R., Klompas A., Gowran A., McKiernan J., Campbell V.A. Endocannabinoids prevent beta-amyloid-mediated lysosomal destabilization in cultured neurons. J Biol Chem 2010, 285:38543-38554.
37. Olivieri G., Baysang G., Meier F., Muller-Spahn F., Stahelin H.B., Brockhaus M., et al. N-acetyl-l-cysteine protects SHSY5Y neuroblastoma cells from oxidative stress and cell cytotoxicity: effects on beta-amyloid secretion and tau phosphorylation. J Neurochem 2001, 76:224-233.
38. Olivieri G., Otten U., Meier F., Baysang G., Dimitriades-Schmutz B., Muller-Spahn F., et al. Beta-amyloid modulates tyrosine kinase B receptor expression in SHSY5Y neuroblastoma cells: influence of the antioxidant melatonin. Neuroscience 2003, 120:659-665.
39. Palazuelos J., Aguado T., Egia A., Mechoulam R., Guzman M., Galve-Roperh I. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J 2006, 20:2405-2407.
40. Palomba L., Sestili P., Cantoni O. tert-Butylhydroperoxide induces peroxynitrite-dependent mitochondrial permeability transition leading PC12 cells to necrosis. J Neurosci Res 2001, 65:387-395.
41. Ramirez B.G., Blazquez C., del Pulgar T.G., Guzman N., de Ceballos M.A.L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005, 25:1904-1913.
42. Richard T., Pawlus A.D., Iglesias M.L., Pedrot E., Waffo-Teguo P., Merillon J.M., et al. Neuroprotective properties of resveratrol and derivatives. Ann NY Acad Sci 2011, 1215:103-108.
43. Rimmerman N., Bradshaw H.B., Kozela E., Levy R., Juknat A., Vogel Z. Compartmentalization of endocannabinoids into lipid rafts in a microglial cell line, which is devoid of caveolin-1. Br J Pharmacol 2011, 10.1111/j. 1476-5381.2011.01380.x.
44. Saito Y., Nishio K., Ogawa Y., Kinumi T., Yoshida Y., Masuo Y., et al. Molecular mechanisms of 6-hydroxydopamine-induced cytotoxicity in PC12 cells: involvement of hydrogen peroxide-dependent and -independent action. Free Radic Biol Med 2007, 42:675-685.
45. Sarker K.P., Maruyama I. Anandamide induces cell death independently of cannabinoid receptors or vanilloid receptor 1: possible involvement of lipid rafts. Cell Mol Life Sci 2003, 60:1200-1208.
46. Sarker K.P., Obara S., Nakata M., Kitajima I., Maruyama I. Anandamide induces apoptosis of PC-12 cells: involvement of superoxide and caspase-3. FEBS Lett 2000, 472:39-44.
47. Scuderi C., Filippis D.D., Iuvone T., Blasio A., Steardo A., Esposito G. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother Res 2009, 23:597-602.
48. Sebestik J., Marques S.M., Fale P.L., Santos S., Arduino D.M., Cardoso S.M., et al. Bifunctional phenolic-choline conjugates as anti-oxidants and acetylcholinesterase inhibitors. J Enzyme Inhib Med Chem 2010, 10.3109/14756366.2010.529806.
49. Sun Y., Alexander S.P., Garle M.J., Gibson C.L., Hewitt K., Murphy S.P., et al. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol 2007, 152:734-743.
50. Tahir S.K., Trogadis J.E., Stevens J.K., Zimmerman A.M. Cytoskeletal organization following cannabinoid treatment in undifferentiated and differentiated PC12 cells. Biochem Cell Biol 1992, 70:1159-1173.
51. Thomas A., Baillie G.L., Phillips A.M., Razdan R.K., Ross R.A., Pertwee R.G. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 2007, 150:613-623.
52. Tolon R.M., Nunez E., Pazos M.R., Benito C., Castillo A.I., Martinez-Orgado J.A., et al. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Res 2009, 1283:148-154.
53. Velez-Pardo C., Jimenez-Del-Rio M., Lores-Arnaiz S., Bustamante J. Protective effects of the synthetic cannabinoids CP55,940 and JWH-015 on rat brain mitochondria upon paraquat exposure. Neurochem Res 2010, 35:1323-1332.
54. Wollen K.A. Alzheimer's disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners. Altern Med Rev 2010, 15:223-244.
55. Yankner B.A., Lu Amyloid T. β-Protein toxicity and the pathogenesis of Alzheimer disease. J Biol Chem 2009, 284:4755-4759.
56. Zhang F., Hong S., Stone V., Smith P.J.W. Expression of cannabinoid CB1 receptors in models of diabetic neuropathy. J Pharmacol Exp Ther 2007, 323:508-515.